Symptoms
Common signs and symptoms of Crigler-Najjar Syndrome include:
When to see a doctor
If you experience severe or worsening symptoms, seek immediate medical attention. Always consult with a healthcare professional for proper diagnosis and treatment.
Causes & Risk Factors
Several factors can contribute to Crigler-Najjar Syndrome.
Crigler-Najjar syndrome results from genetic mutations that disrupt the liver's normal bilirubin processing system.
Crigler-Najjar syndrome results from genetic mutations that disrupt the liver's normal bilirubin processing system. The condition occurs when genes responsible for producing UDP-glucuronosyltransferase 1A1 (UGT1A1), an enzyme crucial for converting bilirubin into a water-soluble form that can be eliminated from the body, contain defects. Type 1 involves complete absence of this enzyme activity, while Type 2 shows severely reduced but not completely absent enzyme function.
The syndrome follows an autosomal recessive inheritance pattern, meaning both parents must carry a copy of the defective gene for their child to develop the condition.
The syndrome follows an autosomal recessive inheritance pattern, meaning both parents must carry a copy of the defective gene for their child to develop the condition. Parents who are carriers typically show no symptoms themselves but have a 25% chance with each pregnancy of having an affected child. The genetic mutations can vary, with over 100 different mutations identified in the UGT1A1 gene, explaining why some families experience more severe symptoms than others.
Bilirubin normally forms when old red blood cells break down as part of the body's natural recycling process.
Bilirubin normally forms when old red blood cells break down as part of the body's natural recycling process. In healthy individuals, the liver quickly processes this bilirubin and eliminates it through bile. When the processing enzyme is missing or severely deficient, bilirubin accumulates in the bloodstream and tissues, creating the characteristic yellow discoloration and potentially toxic effects on the nervous system, particularly the brain and hearing organs.
Risk Factors
- Having two parents who carry the defective gene
- Family history of Crigler-Najjar syndrome
- Consanguineous marriage (marriage between close relatives)
- Certain ethnic backgrounds with higher carrier rates
- Previous child in family with severe neonatal jaundice
- Parents from populations with genetic founder effects
Diagnosis
How healthcare professionals diagnose Crigler-Najjar Syndrome:
- 1
Diagnosis typically begins when newborns develop severe, persistent jaundice that doesn't improve with standard treatments like phototherapy or exchange transfusions.
Diagnosis typically begins when newborns develop severe, persistent jaundice that doesn't improve with standard treatments like phototherapy or exchange transfusions. Pediatricians measure serum bilirubin levels, which in Crigler-Najjar syndrome often exceed 20 mg/dL (compared to normal levels below 1.2 mg/dL in healthy adults). The predominantly unconjugated or indirect bilirubin elevation helps distinguish this condition from other causes of jaundice.
- 2
Genetic testing provides definitive diagnosis by identifying mutations in the UGT1A1 gene.
Genetic testing provides definitive diagnosis by identifying mutations in the UGT1A1 gene. Enzyme activity studies can differentiate between Type 1 and Type 2, with Type 1 showing complete absence of enzyme activity and Type 2 retaining 10% or less of normal function. Additional tests may include liver biopsy to assess tissue structure, though this is less commonly needed with advances in genetic testing.
- 3
Physicians also conduct comprehensive neurological evaluations to check for early signs of kernicterus, including hearing tests, eye examinations, and developmental assessments.
Physicians also conduct comprehensive neurological evaluations to check for early signs of kernicterus, including hearing tests, eye examinations, and developmental assessments. Brain imaging studies like MRI may reveal characteristic patterns of bilirubin deposition in brain tissue. Family genetic counseling often accompanies the diagnostic process to help parents understand inheritance patterns and reproductive options for future pregnancies.
Complications
- The most serious complication of untreated Crigler-Najjar syndrome is kernicterus, a form of brain damage that occurs when high levels of unconjugated bilirubin cross the blood-brain barrier and deposit in brain tissue.
- This condition can cause permanent hearing loss, intellectual disability, movement disorders, and seizures.
- Kernicterus typically develops when bilirubin levels exceed 25-30 mg/dL, though some individuals may be susceptible at lower levels during times of illness or stress.
- Other complications can include chronic fatigue from the demanding treatment schedule, social isolation due to time restrictions imposed by daily phototherapy, and psychological effects from living with a chronic condition.
- Some patients develop skin changes from prolonged light exposure, including premature aging or increased sensitivity.
- Growth and developmental delays may occur if bilirubin levels are not adequately controlled during critical periods of childhood development, emphasizing the importance of consistent treatment adherence and regular monitoring.
Prevention
- Primary prevention of Crigler-Najjar syndrome involves genetic counseling for families with known carrier status or previous affected children.
- Couples can undergo carrier screening through blood tests that identify UGT1A1 gene mutations, particularly important for those with family history of the condition or from populations with higher carrier rates.
- Preimplantation genetic diagnosis allows couples undergoing in vitro fertilization to select embryos without the defective genes.
- Prenatal diagnosis through amniocentesis or chorionic villus sampling can detect the condition during pregnancy, allowing families to prepare for immediate treatment after birth or make informed reproductive decisions.
- Early recognition of carrier status in extended family members helps identify at-risk couples before pregnancy occurs.
- For families with known genetic risk, working closely with maternal-fetal medicine specialists ensures proper delivery planning and immediate availability of phototherapy equipment and pediatric hepatology expertise.
- While the genetic nature of the condition means it cannot be completely prevented, early intervention and prepared medical teams can prevent the most serious complications and improve long-term outcomes for affected children.
Treatment for Crigler-Najjar syndrome focuses on preventing bilirubin levels from reaching dangerous thresholds that could cause brain damage.
Treatment for Crigler-Najjar syndrome focuses on preventing bilirubin levels from reaching dangerous thresholds that could cause brain damage. For Type 1, the most severe form, patients require lifelong phototherapy using special blue lights for 10-12 hours daily to help break down excess bilirubin in the skin. This treatment typically begins immediately after diagnosis and continues throughout the patient's life, though the time requirements may be adjusted based on bilirubin monitoring.
Liver transplantation represents the only definitive cure for Type 1 Crigler-Najjar syndrome, typically recommended when phototherapy becomes less effective or when quality of life significantly deteriorates.
Liver transplantation represents the only definitive cure for Type 1 Crigler-Najjar syndrome, typically recommended when phototherapy becomes less effective or when quality of life significantly deteriorates. The transplant provides a healthy liver capable of producing the missing enzyme, allowing patients to live normal lives without daily phototherapy. Success rates for liver transplantation in Crigler-Najjar patients exceed 90% at specialized centers.
Type 2 patients often respond well to phenobarbital, a medication that can increase the activity of the deficient enzyme by up to five times normal levels.
Type 2 patients often respond well to phenobarbital, a medication that can increase the activity of the deficient enzyme by up to five times normal levels. This treatment can reduce bilirubin levels significantly, sometimes eliminating the need for phototherapy entirely. However, long-term phenobarbital use requires careful monitoring for side effects including sedation, cognitive effects, and potential drug interactions.
Experimental treatments show promise for the future, including gene therapy approaches that could potentially restore normal enzyme function.
Experimental treatments show promise for the future, including gene therapy approaches that could potentially restore normal enzyme function. Hepatocyte transplantation, involving injection of healthy liver cells, has shown some success in small trials. Researchers are also investigating novel phototherapy devices and medications that could improve bilirubin clearance while reducing treatment burden for patients and families.
Living With Crigler-Najjar Syndrome
Living with Crigler-Najjar syndrome requires significant lifestyle adaptations, particularly for those with Type 1 who need daily phototherapy. Families often need to restructure their homes to accommodate phototherapy equipment and create schedules that balance treatment requirements with work, school, and social activities. Many patients receive portable phototherapy devices that allow greater flexibility and mobility while maintaining treatment effectiveness.
Latest Medical Developments
Latest medical developments are being researched.
Frequently Asked Questions
Update History
May 7, 2026v1.0.0
- Published by DiseaseDirectory